Paolo Nuciforo
Overview
Explore the profile of Paolo Nuciforo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
5727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voronova A, Grigoriou A, Bernatowicz K, Simonetti S, Serna G, Roson N, et al.
Med Image Anal
. 2025 Mar;
102:103531.
PMID: 40073583
Diffusion Magnetic Resonance Imaging (dMRI) sensitises the MRI signal to spin motion. This includes Brownian diffusion, but also flow across intricate networks of capillaries. This effect, the intra-voxel incoherent motion...
2.
Pedretti F, Abdalfttah M, Pellegrino B, Mateo F, Martinez-Sanz P, Herencia-Ropero A, et al.
Cancer Res
. 2025 Mar;
PMID: 40067927
Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to poly ADP-ribose polymerase inhibitors (PARPi). HRD also activates the cyclic GMP-AMP synthase (cGAS)-STimulator of INterferon Genes (STING)-Interferon...
3.
Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, et al.
Cell Rep Med
. 2025 Feb;
6(2):101937.
PMID: 39914385
Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We...
4.
El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39846810
Purpose: Innate immune cell-based therapies have shown promising antitumor activity against solid and hematologic malignancies. AFM24, a bispecific innate cell engager, binds CD16A on natural killer (NK) cells/macrophages and EGFR...
5.
Bernatowicz K, Amat R, Prior O, Frigola J, Ligero M, Grussu F, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800381
Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies...
6.
Herencia-Ropero A, Llop-Guevara A, Staniszewska A, Domenech-Vivo J, Garcia-Galea E, Moles-Fernandez A, et al.
Genome Med
. 2024 Aug;
16(1):107.
PMID: 39187844
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is...
7.
Gonzalez-Medina A, Vila-Casadesus M, Gomez-Rey M, Fabregat-Franco C, Sierra A, Tian T, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4491-4504.
PMID: 39078735
Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions...
8.
Macarro C, Bernatowicz K, Garcia-Ruiz A, Serna G, Monreal-Aguero C, Simonetti S, et al.
J Magn Reson Imaging
. 2024 Jun;
61(2):1018-1021.
PMID: 38895928
No abstract available.
9.
Carmona J, Chavarria E, Donoghue K, von Gertten C, Oberrauch P, Pailler E, et al.
Cancer Discov
. 2024 Jun;
14(7):1147-1153.
PMID: 38870393
Cancer Core Europe brings together the expertise, resources, and interests of seven leading cancer institutes committed to leveraging collective innovation and collaboration in precision oncology. Through targeted efforts addressing key...
10.
Prior O, Macarro C, Navarro V, Monreal C, Ligero M, Garcia-Ruiz A, et al.
Radiol Artif Intell
. 2024 Apr;
6(3):e249001.
PMID: 38656233
No abstract available.